You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: PAUL H BROOKES PUBLISHING CO., INC. Topic: Y
DESCRIPTIONprovided by applicantEffective early intervention depends on reliable screening of risk for communication impairments as soon as possibleEstablished infant communication risk factors include poor attentiongesturessocial connectednessexploratory playand speechAlthough these risk factors can be detected bymosand reliably predict later language and social disordersattempts to detect simila ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: CytoInformatics LLC Topic: NIA
DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Novici Biotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately of deaths in developed countries whether idiopathic triggered by environmental factors infections or genetics organ fibrosis results in significant morbidity and mortality Organ fibrosis is responsible for health care costs exceeding $ billion year ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: PROFUSA, INC. Topic: NHLBI
DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: iXpressGenes, Inc. Topic: 100
Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Trans‐nasal delivery of chemotherapy to glioblastoma using magnetic nanoparticles and magnetic focusingSBC: WEINBERG MEDICAL PHYSICS, INC. Topic: 102
Abstract Glioblastoma multiforme GBM is the deadliest form of brain tumor The current treatment includes a combination of surgical resection chemotherapy radiation and electrical disruption of mitosis has only extended survival to approximately to years Preliminary pre clinical findings suggest the potential effectiveness of the candidate drug cyclopamine However the drug is toxic to ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: CardioCreate, Inc. Topic: NHLBI
PROJECT SUMMARY Myocardial regenerative therapy is poised to revolutionize the way heart failure is treated but further improvements and enhanced products are needed to make this therapy truly safe and efficacious Our company CardioCreate Inc has pioneered the use of genetic engineering to enhance the regenerative potential of human Cardiac Progenitor Cells CPCs intended for autologous the ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
SBC: ZYMO RESEARCH CORP. Topic: 101
PROJECT SUMMARY ABSTRACT Stroke injury is a process that occurs over a long duration with pathologic changes that result in long term neurologic dysfunction For stroke there exists an important need for a strategy that can provide safe and efficacious stabilization to the hypoperfused brain and initialize long lasting endogenous neuroprotection for prevention of long term neurologic dysfunction ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
Automated electrophysiological analysis of neural circuitry using a novel nano electrode array for intracellular recording of membrane potentialSBC: CYION TECHNOLOGIES LLC Topic: 101
Summary Nervous systems process information by integrating the electrical activity of neurons in complex networks The alterations in the flow of electrical activity through neuronal networks of the brain play a causal role in the pathogenesis and or the appearance of symptoms of neurodegenerative and psychiatric diseases A fundamental goal of BRAIN Initiative is therefore to elucidate how the ...STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health